Moser JC, Chen D, Hu-Lieskovan S, et al. - Given the unclear optimal front-line treatment for patients with advanced BRAF V600 mutated melanoma, researchers compared overall survival of patients with advanced BRAF mutant melanoma treated with either front-line BRAF/MEKi, anti-PD-1 (aPD-1), or nivolumab and ipilimumab (niv/ipi). From a nationwide database, individuals with advanced BRAF mutant melanoma who had received BRAF/MEKi, niv/ipi, or aPD-1 in the front-line setting were identified comprising de-identified patient-level structured and unstructured data derived from electronic health records. Using Kaplan-Meier curves and log-rank analysis, survival was compared. For this investigation, they identified 567 patients with advanced disease and treated with front-line aPD-1 (n = 162), BRAF/MEKi (n = 297) or niv/ipi (n = 108). Compared with those treated with front-line BRAF/MEKi, patients with advanced BRAF mutant melanoma treated with front-line niv/ipi or aPD-1 had longer survival in the real-world retrospective analysis.